Hugel Inc. Achieves Remarkable Growth in Q3 Financial Results
Hugel Inc., a prominent player in the medical aesthetics field, recently shared its impressive financial performance for the third quarter of 2025. The company celebrated achieving KRW105.9 billion in net sales, which marks a significant milestone, showcasing its continuous growth in the global market.
Strong Operating Profit and Net Income Figures
For the third quarter, Hugel reported an operating profit of KRW47.4 billion and a net income of KRW38 billion. These figures highlight the company's ability to sustain profitability, reflected in a robust gross profit margin of 77% and an operating profit margin of 45%. It's noteworthy that this marks two consecutive quarters where the company has exceeded KRW100 billion in net sales.
Global Market Expansion Drives Performance
The impressive results were largely attributed to strong global sales of Hugel's flagship products, including botulinum toxin and hyaluronic acid dermal fillers. The company also saw considerable growth in its cosmetics line despite facing heightened competition in the domestic market.
Approximately 80% of net sales from botulinum toxin and dermal fillers originated from exports, reflecting a year-on-year increase of around 11% to KRW72.6 billion. Notably, sales in key markets like the US, China, Europe, and Brazil represented about 45% of total sales, significantly contributing to Hugel's overall success.
Key Product Sales Breakdown
When analyzing sales by product category, botulinum toxin, marketed globally under the brand name Letybo, achieved net sales of KRW60.2 billion in the third quarter. Additionally, dermal fillers known as Revolax garnered KRW30.2 billion in sales, while the WELLAGE and BYRYZN BR cosmetics brands reported a remarkable KRW14.9 billion in quarterly net sales, experiencing an impressive 65% growth compared to the previous year.
Leadership Insights on Future Growth
Expressing optimism about the company's continued success, Carrie Strom, President and Global CEO of Hugel, remarked, "We are very encouraged by the sales growth and market uptake across the world's four largest toxin markets – the US, China, Europe, and Brazil. We expect our businesses in these regions to remain a key growth driver moving forward." This statement underscores Hugel's strategic focus on expanding its influence in crucial global markets.
About Hugel Inc.
Established in 2001, Hugel has emerged as a leader in the medical aesthetics industry, specializing in the development of injectables that promote skin rejuvenation. The company's product lineup includes botulinum toxin, hyaluronic acid fillers, skin boosters, and absorbable sutures, alongside an array of cosmetic items. Hugel prides itself on its commitment to safety and quality, striving to push the boundaries of the industry through solid medical affairs, extensive training initiatives, and vibrant industry discussions.
Over the past two decades, the company has expanded its reach to about 70 countries and operates nine subsidiaries worldwide, including in regions such as the US, Australia, Canada, Taiwan, China, Hong Kong, Singapore, and Thailand. With a strong focus on industry momentum, Hugel is ideally positioned to continue its growth trajectory and market expansion.
Contact Information
For further inquiries, reach out to Jihyun Kim, Manager of the PR Team at Hugel.
Frequently Asked Questions
What were Hugel's major financial results for Q3 2025?
Hugel reported KRW105.9 billion in net sales, an operating profit of KRW47.4 billion, and a net income of KRW38 billion for the third quarter of 2025.
What contributed to Hugel's robust sales performance?
Strong global sales of botulinum toxin and hyaluronic acid dermal fillers, alongside growth in its cosmetics business, significantly drove the company's sales growth.
Which markets are key for Hugel's growth strategy?
The company's performance is particularly strong in the US, China, Europe, and Brazil, where it continues to see substantial market uptake and growth.
How has Hugel's product line evolved over the years?
Founded in 2001, Hugel specializes in injectables for skin rejuvenation, including botulinum toxin and dermal fillers, while also expanding into cosmetics and other aesthetic solutions.
What is the commitment of Hugel toward quality and safety?
Hugel emphasizes a strong commitment to safety and quality in all its products, reinforcing this through extensive medical affairs and training programs.
